news

Epigenetic qPCR tool detects disease in newborns

1
SHARES

The alternative method uses epigenetic quantitative real-time PCR (qPCR) assays and successfully detects a larger number of PIDs…

primary

A new study has identified a novel diagnostic approach to screen newborns for inherited diseases that are not presently screened for.

 

SPACES ARE FILLING FAST – SECURE YOURS!


Rapid sterility testing is no longer optional for advanced therapies – it’s becoming operationally essential. Join this webinar to explore rapid sterility testing methods that ensure fast, reliable product release, addressing critical challenges in timely delivery and safety.

Harnessing digital PCR for rapid sterility testing

18 March 2026 | 3PM

What you’ll discover:

  • Rapid sterility testing methods that address the challenge of lengthy testing times, improving efficiency and ensuring timely product release
  • Insights into how digital PCR technology enhances testing accuracy and sensitivity, detecting contaminants quickly and reliably
  • Real-world case studies on rapid testing implementations in the field of cell and gene therapy

The session will discuss future trends in sterility testing and showcase successful rapid sterility testing in cell and gene therapy products, demonstrating practical applications and benefits.

Register now to join live or for free access to the on-demand recording if you can’t make the date

Currently, newborns undergo a ‘heel-prick’ test, and the dried blood spots are analysed for Severe Combined Immunodeficiencies (SCID). Despite more than 300 Primary Immune Deficiencies (PIDs) are known, in the UK, the test checks for signs of only 9 diseases including sickle cell disease, cystic fibrosis, congenital hypothyroidism and other inherited metabolic disorders.

The alternative method uses epigenetic quantitative real-time PCR (qPCR) assays and successfully detects a larger number of PIDs, including SCIDs and immune dysregulation, X-linked agammaglobulinemia (XLA) and other severe diseases that usually become apparent within a few months of birth.

“While further research is needed, these initial results are very encouraging as they provide early evidence that this epigenetic technology could eventually be a newborn screening method that would identify primary immune diseases that are currently very difficult to detect,” said Dr Rosa Bacchetta, one of the study investigators and an Associate Professor in the Department of Paediatrics, Stanford School of Medicine.

The new method could allow treatment to begin soon after birth, with improved disease outcomes and better survival.

“Typically, children are not diagnosed until they’re sick and are showing symptoms at which point there already is organ impairment and infections that make effective treatment much more difficult. It would be highly advantageous if we could identify these diseases at birth and begin treatment soon after birth, prior to the development of symptoms.”

In the study, epigenetic qPCR assays were developed to analyse human leukocyte subpopulations. Blood from 25 healthy individuals and 97 HIV positive individuals along with dried blood spots from 250 healthy newborns and 24 newborns with primary immunodeficiencies were analysed.

The study showed successful identification of newborns suffering from various primary immunodeficiencies using epigenetic immune cell quantification, and as such, could expand the number of life threatening immune disorders identified in newborns. Earlier detection could lead to more successful treatment, and an overall longer, healthier life.

The researchers continue to investigate epigenetic immune monitoring on healthy children in order to provide more precise diagnostics to detect these diseases.

The study was published in Science Translational Medicine.

Share via
Share via